<DOC>
	<DOC>NCT01623453</DOC>
	<brief_summary>This is an open follow-up clinical trial to evaluate a sustained efficacy and safety of ANTG-ASC injection for 4 months (6 months after final dose injection) after Phase II clinical trial.</brief_summary>
	<brief_title>Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)</brief_title>
	<detailed_description />
	<mesh_term>Fistula</mesh_term>
	<criteria>the patients who have participated in ANTGASC210 clinical trial the patients with complete closure at week 8 after last injection in ANTGASC210 trials the patients who submit written informed consents and is able to obey requirements of trials a patient who has a history of variant Creutzfeldt Jacobs disease or related diseases a patient who is allergic to anesthetics, bovine derived proteins or a fibrin glue a patient who has an autoimmune disease a patient who has infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) a patient who has a symptom of septicemia or active tuberculosis (contain tuberculosis of anus and rectum) a patient who is pregnant or breast feeding a patient who is not willing to use effective contraceptive methods during the study a patient who has inflammatory Bowel disease a patient who is sensitive to fibrin glue a patient who have a clinically relevant history of abuse of alcohol or drugs, habitual smoker (who smoked more than 20 cigarettes a day) a patient who is not able to understand the objective of this study or to comply with the study requirements a patient who is considered to have a significant disease which can impact the study by investigator a patient who is considered not suitable for the study by investigator a patient who had a history of surgery for malignant tumor within the last five years (except carcinoma in situ) a patient who has multisystemic wasting syndrome (such as tuberculosis, Diabetes, Thyroid disorders, tumor, etc.) a patient who has taken cytotoxic drugs (such as immunosuppressants, corticosteroid, cytotoxic chemotherapy, anticoagulants, etc.) during longterm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>crohn's disease</keyword>
	<keyword>fistula</keyword>
	<keyword>complex</keyword>
</DOC>